Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
LONDON, Sept 16 (Reuters) - Britain's biggest drugmaker GlaxoSmithKline said it had been forced to shut a factory at Maidenhead west of London due to flooding, potentially causing disruption to the site which produces toothpaste and mouthwash. A spokesman said GSK closed the plant at around
Read more
(ShareCast News) - After its Shingrix shingles vaccine proved extremely successful in a trial among elderly patients, GlaxoSmithKline has begun planning regulatory applications for later this year. In a Phase III study on adults 70 years' old or above, two doses of Shingrix showed 90% efficiency com
Read more(Adds details on drug, FDA recommendation) By Natalie Grover Sept 14 (Reuters) - A serious warning on Pfizer Inc's quit smoking drug should be removed, 10 of 19 independent panelists to the U.S. Food and Drug Administration recommended on Wednesday, after reviewing additional trial d
Read moreBy Gene Emery Sept 14 (Reuters) - GlaxoSmithKline's experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to data published on Wednesday. In clinica
Read more(Recasts with growth outside home market; adds CEO comment; adds smaller rival) JOHANNESBURG, Sept 14 (Reuters) - South Africa's Aspen Pharmacare Holdings will use its recent acquisitions of GlaxoSmithKline and AstraZeneca product lines to move into China, the firm's chief executive said.Read more
(ShareCast News) - GVC Holdings: Berenberg reiterates buy with a target price of 760p. Softcat: Citigroup reiterates buy, 410p target. GlaxoSmithKline: Jefferies downgrades to underperform with a 2300p target. Relx: UBS stays at buy with a 1600p target. GB Group: Citigroup starts coverage at buy
Read more(Adds Verily CMO interview, background) PARIS, Sept 12 (Reuters) - French drugmaker Sanofi and Verily, the life sciences unit of Google parent Alphabet Inc, on Monday said they would invest about $500 million in a joint venture combining devices with services to improve diabetes care, an e
Read more(Recasts, adds quotes, context) By William James LONDON, Sept 12 (Reuters) - Britain will make public its guidelines for talks on leaving the European Union by the time it triggers the exit process, Brexit minister David Davis said on Monday, in the first indication of when Britons wi
Read more(ShareCast News) - GlaxoSmithKline has applied to the European drug regulator to approve its rheumatoid arthritis treatment, sirukumab, which some analysts predict could generate at least £1bn a year within five years. GSK confirmed on Monday that it applied to the European Medicines Agency for appr
Read more(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac
Read moreLONDON, Sept 12 (Reuters) - GlaxoSmithKline is to sell its portfolio of anaesthetic drugs to South Africa's Aspen Pharmacare for up to 280 million pounds ($372 million) as part of a drive by the British drugmaker to focus on core therapy areas. The two firms, which have a long history of wo
Read moreBy Ben Hirschler LONDON, Sept 6 (Reuters) - An experimental three-in-one inhaled drug from GlaxoSmithKline significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday. GSK is ahead of rivals AstraZeneca and Novartis in developing
Read more(ShareCast News) - Tests of a GlaxoSmithKline respiratory drug have found a statistically significant reduction in the rate of attacks suffered by chronic obstructive pulmonary disease (COPD) patients compared to when they receive the standard treatment. The pioneering Salford Lung Study by GSK and
Read more* Benralizumab effective given once every 8 weeks * Cuts annual rate of asthma exacerbations by up to half * AZ aims to take on recently launched GSK, Teva drugs By Ben Hirschler LONDON, Sept 5 (Reuters) - AstraZeneca hopes to convince doctors its experimental injection fo
Read more(ShareCast News) - Pearson: JP Morgan reiterates neutral with a target price of 940p. Vodafone: UBS maintains buy with a 310p target. Glaxosmithkline: UBS keeps at neutral with a 1650p target. GKN: Canaccord reiterates buy with a 370p target. Legal & General: Macquarie keeps at neutral with a tar
Read more
Last checked at